Related Experiment Video
Updated: Feb 23, 2026
07:51
A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
11.1K
Atomoxetine in abstinent cocaine users: Sex differences
Elise E DeVito1,2, Aryeh I Herman1,2, Noah S Konkus1
1Department of Psychiatry, Yale School of Medicine, United States.
Data in Brief
|September 2, 2017
Summary
This study examined atomoxetine effects in cocaine use disorder patients. Atomoxetine did not significantly alter subjective drug effects, cognitive performance, or cardiovascular measures in abstinent individuals.
Area of Science:
- Neuroscience
- Psychopharmacology
- Addiction Medicine
Background:
- Cocaine use disorder (CUD) is a significant public health issue.
- Pharmacological interventions for CUD are limited.
- Atomoxetine, a norepinephrine reuptake inhibitor, has shown potential in treating substance use disorders.
Purpose of the Study:
- To investigate the effects of atomoxetine on subjective drug effects, cognitive performance, and cardiovascular measures in abstinent individuals with CUD.
- To conduct a secondary analysis focusing on sex differences in response to atomoxetine.
Main Methods:
- A human laboratory investigation involving a secondary analysis of sex differences.
- Participants: abstinent individuals with CUD.
- Intervention: single doses of atomoxetine (40 mg and 80 mg) or placebo.
- Assessments: subjective drug effects, cognitive performance, cardiovascular measures.
Main Results:
- Atomoxetine (40 mg and 80 mg) did not produce statistically significant differences compared to placebo across subjective drug effects, cognitive performance, or cardiovascular measures.
- No significant sex differences were observed in the response to atomoxetine.
Conclusions:
- Single doses of atomoxetine were not found to be effective in altering subjective drug effects, cognitive performance, or cardiovascular measures in abstinent individuals with CUD.
- Further research is warranted to explore the efficacy of atomoxetine, potentially at different doses or durations, for CUD treatment.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
1.0K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.0K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
974
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
974
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.8K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.8K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.9K
01:15Drug Abuse and Addiction: Pharmacological Phenomena
1.3K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.3K